Printer Friendly

TOLL-FREE NUMBER AVAILABLE FOR TAXOTERE(R) CLINICAL TRIALS

 COLLEGEVILLE, Pa., June 2 /PRNewswire/ -- Rhone-Poulenc Rorer (NYSE: RPR) announced today the initiation of a toll-free clinical trial hotline called 1-800-RX TRIAL.
 The new phone service was created to allow easy access by both physicians and patients to information on Rhone-Poulenc Rorer-sponsored clinical trials of an investigational anticancer drug, Taxotere(R).
 Callers will be greeted by clinical specialists who pre-screen callers and direct them to the appropriate clinical trial site. If a patient is not eligible for a Taxotere(R) clinical trial, they are directed to another cancer hotline, such as 1-800-4 CANCER for more information.
 "Clinical trials are the only means of demonstrating the safety and efficacy of a new compound," said Terry Plasse, M.D., Director of Oncology at Rhone-Poulenc Rorer. "We hope the toll-free number will help identify patients and physicians who can benefit from learning about entry criteria and trial site location. Together, we can aid in the fight against cancer by increasing the speed with which a new drug comes to market."
 Taxotere(R) is currently being tested in the following cancer types: breast, ovarian, non small-cell lung, adult acute leukemia, pediatric tumors, melanoma, non-Hodgkin's lymphoma, soft tissue sarcoma, and cancers of the stomach, prostate, pancreas, bladder, cervix and head and neck.
 Taxotere(R) belongs to a unique class of anti-cancer agents called taxoids. Taxoids have been found to inhibit cancer cell division by acting on the cell's internal skeleton, which is made up of elements called microtubules. Microtubules assemble and disassemble during the cell cycle, but Taxotere blocks the disassembly, thus preventing cancer cells from dividing.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. The company reported sales of $4.1 billion and invested over $500 million in research and development in 1992.
 /delval/
 -0- 6/2/93
 /CONTACT: Bob Pearson of Rhone-Poulenc Rorer, 215-454-3872/
 (RPR)


CO: Rhone-Poulenc Rorer ST: Pennsylvania IN: MTC SU: PDT

MK -- PH003 -- 4310 06/02/93 09:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1993
Words:330
Previous Article:H.J. HEINZ COMPANY APPOINTS AREA DIRECTOR-ASIA/PACIFIC
Next Article:AMERICAN RESIDENTIAL ADDS MIDWEST OFFICES; COMPANY MOVES TO TAP STRONG HOME-BUYING MARKETS
Topics:


Related Articles
BREAST CANCER CLINICAL TRIALS OPEN IN READING AREA; INFORMATION AVAILABLE VIA TOLL-FREE NUMBER
RPR SUBMITS NDA FOR TAXOTERE(R)(docetaxel) IN JAPAN; WORLDWIDE SUBMISSION TO OCCUR IN THIRD QUARTER
RPR SUBMITS NDA FOR TAXOTERE(R)(docetaxel) IN JAPAN; WORLDWIDE SUBMISSION TO OCCUR IN THIRD QUARTER
A NEW CLINICAL TRIAL FOR NON-SMALL CELL LUNG CANCER IS STARTED AS PART OF TAXOTERE(R) RESEARCH BY RHoNE-POULENC RORER
TAXOTERE(R) (docetaxel) APPROVED IN CANADA FOR TREATMENT OF ADVANCED BREAST AND NON-SMALL CELL LUNG CANCER
TAXOTERE(R)(DOCETAXEL) APPROVED IN BRAZIL FOR TREATMENT OF ADVANCED BREAST AND NON-SMALL CELL LUNG CANCER;
TAXOTERE(R) (docetaxel) RECOMMENDED FOR APPROVAL IN AUSTRALIA FOR TREATMENT OF ADVANCED BREAST AND NON-SMALL CELL LUNG CANCER
NEW ANTICANCER AGENT, TAXOTERE(R) (docetaxel), NOW AVAILABLE TO TREAT ADVANCED BREAST CANCER IN IRELAND
NEW ANTICANCER AGENT, TAXOTERE(R) (docetaxel), NOW APPROVED TO TREAT ADVANCED BREAST AND NON-SMALL CELL LUNG CANCER IN CZECH REPUBLIC
TAXOTERE (docetaxel) CLEARED FOR USE AS A TREATMENT FOR PATIENTS WITH ADVANCED BREAST CANCER IN UNITED STATES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters